Photonis Launches Two Market-Leading Solutions to Advance Single Photon Detection and Imaging Applications
Advancing Photon Detection and Imaging: Photonis Unveils Cricket™ Pro and PhotonPix™
SAN FRANCISCO, CA / ACCESS Newswire / January 23, 2025 / Photonis, a leading brand of Exosens and global leader in advanced photon detection and imaging solutions, proudly announces the launch of Cricket™ Pro and PhotonPix™. Designed to redefine the possibilities of single photon detection and imaging, these cutting-edge solutions empower researchers and industry professionals to achieve unparalleled performance across applications such as biomedical imaging, quantum science, and high-energy physics.Cricket Pro and PhotonPix
These technologies will officially debut at SPIE Photonics West 2025 in San Francisco, CA.
Cricket™ Pro: Transforming Low-Light Imaging with High-Speed Precision
The Cricket™ Pro brings unprecedented imaging capabilities for low-light and single-photon imaging applications. This innovative, plug-and-play image intensifier adapter easily fits any professional, scientific, F-Mount camera, delivering high resolution and ultra-high-speed functionality for demanding low-light applications. Key features of the Cricket™ Pro include:
Expanded 25 mm active detection area
High-speed gating as fast as 3 nanoseconds
Remarkable 3 MHz Burst or 30kHz repetition rate
Matched with High-performance Photonis Image Intensifier
F-Mount lens/camera interface
Fully integrated power and gating electronics
With these enhancements, Cricket™ Pro sets a new benchmark for scientific imaging, providing precise, rapid, and reliable performance tailored for researchers and industry professionals.
PhotonPix™: Ultra High-Count Rate Module for Single-Photon Detection
Photonis also proudly introduces PhotonPix™, a high-count rate MCP-PMT-based plug-and-play module engineered for ultra-high timing precision single-photon detection. Combining state-of-the-art technology with user-centric design, PhotonPix offers:
An Ø8 mm sensitive area
Extreme-low dark count rate as low as 20 cps
Count rates exceeding 200 MHz in Burst mode, making it ideal for high-demand applications
Timing resolution below 15 ps for unmatched precision
PhotonPix™ is ideal for ultra-fast Single Photon Detection and time-correlated applications such as LIDAR, Photon Entanglement, or Lifetime Imaging. The module's versatility accommodates various high-quantum-efficiency (Hi-QE) photocathodes from Photonis, covering the spectrum range from 150nm to 900nm, making it the perfect fit for researchers and industry professionals.
Experience the Future of Photon Detection and Imaging
Discover how the Cricket™ Pro and PhotonPix™ can transform your research and applications. Visit Photonis at Booth #1827 during SPIE Photonics West 2025 to see live demonstrations and connect with our experts.
ABOUT PHOTONIS:
Photonis is a leading product brand of Exosens, a high-tech company with more than 85 years of experience in the innovation, development, manufacture and sale of high-end electro-optical technologies. Photonis offers its customers photo-detection and low light conditions imaging solutions for extremely demanding environments such as Defense & Security, Nuclear Safety, Life Science and Industrial & Non-Destructive testing. Photonis is internationally recognized as a leading brand and a major innovator in its fields with production and R&D sites in Europe and North America.
Contact Information
Sales Manager
science@exosens.com
+31 50 501 8808
SOURCE: Exosens
View the original press release on ACCESS Newswire
Exosens
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma17.11.2025 13:00:00 CET | Press release
OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. TAIPEI, TW / ACCESS Newswire / November 17, 2025 / OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology. Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the United States and a 5-year survival rate ranging from 2% and 23% depending on disease stage, histological subtype, and localization 1 . At present, there are no FDA approved ADC therapies for cholangiocarcinoma. To encourage the industry to develop new treatment options for rare diseases, the US FDA grants Orphan Drug Designation to exper
Camino Completes C$5.6 Million Investment with Strategic Investors17.11.2025 12:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / November 17, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC:CAMZF) ("Camino" or the "Company") is pleased to announce the closing of its -brokered private placement (the "Financing") of common shares in the capital of the Company (the "Shares") previously announced in its news release dated November 12, 2025. Under the Financing, the Company issued an aggregate of 15,554,666 Shares at an issue price of $0.36 per Share, for aggregate gross proceeds of C$5,599,680. Participants in the Financing included two new key shareholders, Elemental Royalties (formerly EMX Royalty Corp.) and Continental General Insurance Company, as well as certain insiders of Camino. The gross proceeds of the Financing will be applied towards corporate working capital, legal expenses, engineering studies, project development, and general administrative expenses. The Shares issued pursuant to the Financing are subject to a statutory hold period expiring on March 15, 2026, in acc
GA-ASI Completes Full-Scale Fatigue Test on MQ-9B17.11.2025 03:10:00 CET | Press release
MQ-9B's Third Lifetime Test Completes the FSF Testing Process With a Total of 120,000 Hours DUBAI, UAE / ACCESS Newswire / November 16, 2025 / On October 31, 2025, General Atomics Aeronautical Systems, Inc. (GA-ASI) completed its "third lifetime" of full-scale fatigue (FSF) testing for the MQ-9B Remotely Piloted Aircraft (RPA). Completion of FSF testing for the third and final lifetime includes a total of 120,000 operating hours (40,000+ flight hours per aircraft life) for the RPA and is a key milestone in validating the design of the airframe. The testing verifies the airframe structural integrity in support of certification to the NATO STANAG 4671 standard. The aim of the testing is to identify any potential structural deficiencies ahead of fleet usage and assist in developing inspection and maintenance schedules for the airframe. Test results will be used as documentation for certification and will form the basis for in-service inspections of structural components. "The completion o
GA-ASI and Saab Will Demonstrate AEW&C on MQ-9B in 202617.11.2025 03:05:00 CET | Press release
Two Aerospace Leaders Are Bringing Airborne Early Warning and Control to UAS DUBAI, UAE / ACCESS Newswire / November 16, 2025 / Following their announcement to bring Airborne Early Warning and Control (AEW&C) capability to the world's leading Remotely Piloted Aircraft (RPA) platform, General Atomics Aeronautical Systems, Inc. (GA-ASI) and Saab will now team up to demonstrate the capability in the summer of 2026. The demo will be conducted at GA-ASI's Desert Horizon flight operations facility in Southern California using a GA-ASI MQ-9B equipped with AEW&C supplied by Saab. In partnership with Saab, a leading company in AEW&C systems, GA-ASI is pairing Saab's AEW sensors with the world's longest-range, highest-endurance RPA, the MQ-9B. At sea or over land, adding AEW capabilities on MQ-9B enables persistent air surveillance and enables AEW in areas of the world where it doesn't currently exist or is unaffordable, such as for navy aircraft carriers at sea. "Adding AEW&C to the MQ-9B bring
Doha Tattoo Festival Announced as Ticket Sales Officially Open16.11.2025 12:45:00 CET | Press release
DOHA, QA / ACCESS Newswire / November 16, 2025 / Under the patronage of His Excellency Sheikh Khalifa bin Hamad bin Khalifa Al Thani, Minister of Interior and Commander of the Internal Security Force (Lekhwiya), the first edition of the Doha International Music and Marching Festival (Doha Tattoo) will be held from 16 to 20 December 2025 at Katara Cultural Village. A press conference held at Katara Cultural Village unveiled the line-up of participating bands and ticket details, attended by members of the Doha Tattoo organising committee and partner representatives. The Doha Tattoo will combine precision with musical artistry, showcasing performances by distinguished musical bands from seven countries: the United Kingdom, the United States of America, Turkia, Hashemite Kingdom of Jordan , the Sultanate of Oman, Kazakhstan, and the State of Qatar. The participating line-up includes the Irish Guards and the Royal Air Force Music Services from the United Kingdom, the United States Air Force
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom